TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Risk of developing colorectal dysplasia or cancer
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of acute complications
Endpoint domain: Adverse events/effects
Primary endpoint: Late adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: thrombus clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cartilage volume loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: GDM rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: homeostasis model assessment of insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean color difference of white spot lesions vs sound adjacent enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvements in anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvements in somatization
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Breast cancer risk estimate
Endpoint domain: Mortality/survival
Primary endpoint: macronutrient intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: brown bread intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Left ventricular work index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of venous thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Increased intake of carotene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recurrent disease rate
Endpoint domain: Mortality/survival
Primary endpoint: Trial completion rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: plasma tHcy levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum hs-CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: S-TRACP5b
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S-CTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S-PINP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sequelae on postradiation angiography
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge of fertility issues
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge of infertility risk factors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge of the definition of infertility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IRLS severity category
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI‐1 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of etoposide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central volume of distribution of etoposide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in skin scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in joint involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Insulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: C-peptide concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Importance of stopping smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confidence to stop smoking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean postoperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative hypoxaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inflammatory mediators levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Suture retention rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cognitive test of executive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy intake after pre-meal load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ratings of fullness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mortality at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: decrease in allopregnanolone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: IL-12p35/IL-10 mRNA ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of cardiovascular outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial distensibility and compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Arterial stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Decreases in serum and urine concentrations of markers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in TUG time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 40-m SPWT speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 30 CST repetitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 20-cm step test steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of shivering threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-inflammatory effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tinnitus loudness and annoyance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LRA (Lower limb Range of motion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait cadence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower extremity muscles endurance level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiorespiratory endurance level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MVA time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post MVA pain score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Satisfactory score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: degree of aphasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VLDL reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Triglyceride reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Selective attention improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in omission error in divided attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of men undergoing a BMD test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue pethidine requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total effectiveness rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence rate of common complications
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of fibromyalgia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Coping strategies
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prediction of PHV (Peak Height Velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PC20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for oral corticosteroids for asthma exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: Median prescription refills for inhaled corticosteroids
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of nebulizations given
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of oxygen therapy required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total protein in BALF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative content of large surfactant aggregates (LA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum surface tension of LA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of gastric cancer or precancerous lesions
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in plasma 8‐isoprostane levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in plasma oxLDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in total plasma Lp‐PLA2 activity and mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loss of disc space height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in 'on' time with dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Well-being as measured by PGWB Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of infants within the PaCO2 target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for blood and blood product transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increase in paranoia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of injections received during last 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of injections received
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health seeking during the past 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or cardiovascular hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Reoperation for valve failure
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction with choice
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: subject reported pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physician rated procedure difficulty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CBCL total problem scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Externalising problem scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Internalising problem scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean time to 70% recovery of Train-of-Four ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint Reaction Force (JRF) peaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to peritoneal recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Half-time of gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postprandial dyspeptic symptom score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of pain perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative change in ASGP-R concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of post- to pre-operative 99mTc-GSA clearance of unit hepatic functional volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean minimum systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Doses of ephedrine required to treat hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: isokinetic peak torques of knee flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ECCKF/CONKE ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: albumin loss in ultrafiltrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biocompatibility of hemofilters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Arterial Pressure (MAP) drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Walking speed (T25FW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate for unilateral spinal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: duration of motor and sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: failure of respiratory support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: hypercarbonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry functional score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Vertebral height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores at 4 and 8 h postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total analgesic consumption during the first 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall patient's and surgeon's satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of SPN-812 in treating ADHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of SPN-812
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of SPN-812
Endpoint domain: Adverse events/effects
Primary endpoint: Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of ventricular tachyarrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total plasma beta-carotene concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reattempted suicide
Endpoint domain: Mortality/survival
Primary endpoint: Pain level (visual analogue scale)
Endpoint domain: Adverse events/effects
Primary endpoint: Time taken for treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in FEV1% predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Times to next exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart failure symptoms (NYHA class)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of heart failure recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Maintenance of SR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left atrial area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative azoospermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in glucose levels post-meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bioavailability of enteral fluconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG changes (delta and alpha waves)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Satisfied anesthesia rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative rescuing sufentanil usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: arterial oxygen tension/fraction of inspired oxygen (PaO2/FIO2) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: weaning time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: respiratory infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Fentanyl requirement during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of eyes with BCVA of 20/40 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of progression of macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Support for FGM among mothers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: plasma triglyceride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: concentration of total very-low-density lipoprotein (VLDL) particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL particle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Size of infarct area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ACR Pediatric‐30 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pus-covered area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: volume of ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Posterior capsule opacification (PCO) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nd:YAG capsulotomy rate
Endpoint domain: Mortality/survival
Primary endpoint: Rate of confirmed angioedema attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of TM color changes with effusion presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viscosity of effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum plasma concentration of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the curve of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased sedentary behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased portion control behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased unhealthy weight control behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in body image
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvements in self-worth
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients free from angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALT elevation incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Association between NTM lymphadenitis and +3953TT in IL1B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protection from disease linked to ‐592C/A heterozygosity in IL10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Jadad score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes